Prophylactic and therapeutic protection of human IgG purified from sera containing anti-exotoxin A titers against pneumonia caused by Pseudomonas aeruginosa

References

• Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon? Curr Infect Dis Rep. 2018;20:23. doi:10.1007/s11908-018-0629-6.
   PubMed Web of Science ®Google Scholar
• Wieland K, Chhatwal P, Vonberg RP. Nosocomial outbreaks caused by Acinetobacter baumannii and Pseudomonas aeruginosa: results of a systematic review. Am J Infect Control. 2018;46:643–48. doi:10.1016/j.ajic.2017.12.014.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao C, Chen H, Li H, Wang Q, Wang Z, Zhang F, Wang H. A multicenter epidemiology study on the risk factors and clinical outcomes of nosocomial intra-abdominal infections in China: results from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) 2007-2016. Infect Drug Resist. 2018;11:2311–19. doi:10.2147/IDR.S182180.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24:385–93. doi:10.1097/MCC.0000000000000534.
   PubMed Web of Science ®Google Scholar
• Francois B, Luyt CE, Stover CK, Brubaker JO, Chastre J, Jafri HS. New strategies targeting virulence factors of staphylococcus aureus and Pseudomonas aeruginosa. Semin Respir Crit Care Med. 2017;38:346–58. doi:10.1055/s-0037-1602715.
   PubMed Web of Science ®Google Scholar
• Ali SO, Yu XQ, Robbie GJ, Wu Y, Shoemaker K, Yu L, DiGiandomenico A, Keller AE, Anude C, Hernandez-Illas M, et al. Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosa PcrV and Psl bispecific human monoclonal antibody, in healthy adults. Clin Microbiol Infect. 2019;25:629.e621-629.e626. doi:10.1016/j.cmi.2018.08.004.
   Web of Science ®Google Scholar
• Armstrong S, Yates SP, Merrill AR. Insight into the catalytic mechanism of Pseudomonas aeruginosa exotoxin A. Studies of toxin interaction with eukaryotic elongation factor-2. J Biol Chem. 2002;277:46669–75. doi:10.1074/jbc.M206916200.
   PubMed Web of Science ®Google Scholar
• Wretlind B, Pavlovskis OR. The role of proteases and exotoxin A in the pathogenicity of Pseudomonas aeruginosa infections. Scand J Infect Dis Suppl. 1981;29:13–19.
   PubMedGoogle Scholar
• Manafi A, Kohanteb J, Mehrabani D, Japoni A, Amini M, Naghmachi M, Zaghi AH, Khalili N. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol. 2009;9:23. doi:10.1186/1471-2180-9-23.
   PubMed Web of Science ®Google Scholar
• Jiang M, Yao J, Feng G. Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS One. 2014;9:e96609. doi:10.1371/journal.pone.0096609.
   PubMed Web of Science ®Google Scholar
• Fogle MR, Griswold JA, Oliver JW, Hamood AN. Anti-ETA IgG neutralizes the effects of Pseudomonas aeruginosa exotoxin A. J Surg Res. 2002;106:86–98.
   PubMed Web of Science ®Google Scholar
• Head BM, Rubinstein E, Meyers AF. Alternative pre-approved and novel therapies for the treatment of anthrax. BMC Infect Dis. 2016;16:621. doi:10.1186/s12879-016-1987-z.
   PubMed Web of Science ®Google Scholar
• Navalkele BD, Chopra T. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018;12:11–21. doi:10.2147/BTT.S127099.
   PubMed Web of Science ®Google Scholar
• Sawa T, Ito E, Nguyen VH, Haight M. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa. Hum Vaccin Immunother. 2014;10:2843–52. doi:10.4161/21645515.2014.971641.
   PubMed Web of Science ®Google Scholar
• Milla CE, Chmiel JF, Accurso FJ, VanDevanter DR, Konstan MW, Yarranton G, Geller DE. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol. 2014;49:650–58. doi:10.1002/ppul.22890.
   PubMed Web of Science ®Google Scholar
• Katoh H, Yasumoto H, Shimizu M, Hamaoka S, Kinoshita M, Akiyama K, Sawa T. IV immunoglobulin for acute lung injury and Bacteremia in Pseudomonas aeruginosa Pneumonia. Crit Care Med. 2016;44:e12–24. doi:10.1097/CCM.0000000000001271.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Kato H, Yasumoto H, Shimizu M, Hamaoka S, Naito Y, Akiyama K, Moriyama K, Sawa T. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Hum Vaccin Immunother. 2016;12:2833–46. doi:10.1080/21645515.2016.1209280.
   PubMed Web of Science ®Google Scholar
• Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, Levato D, Nobile F, Carotenuto M, Liso V, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81:121–26.
   PubMed Web of Science ®Google Scholar
• Joao C, Ogle BM, Geyer S. Immunoglobulin promotes the diversity and the function of T cells. Eur J Immunol. 2006;36:1718–28. doi:10.1002/eji.200635908.
   PubMed Web of Science ®Google Scholar
• Pires AE, Afonso AF, Queiros A, Cabral MS, Porrata L, Markovic SN, Kaveri SV, Da Silva MG, João C. Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation. J Immunother. 2010;33:618–25. doi:10.1097/CJI.0b013e3181d3cb19.
   PubMed Web of Science ®Google Scholar
• Finck-Barbancon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleiszig SM, Wu C, Mende-Mueller L, Frank DW. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol. 1997;25:547–57.
   PubMed Web of Science ®Google Scholar
• Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by Pseudomonas aeruginosa lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1. Infection and Immunity. 2002;70:1352–58. doi:10.1128/iai.70.3.1352-1358.2002.
   PubMed Web of Science ®Google Scholar
• Schultz MJ, Rijneveld AW, Florquin S, Speelman P, Van Deventer SJ, van der Poll T. Impairment of host defence by exotoxin A in Pseudomonas aeruginosa pneumonia in mice. J Med Microbiol. 2001;50:822–27. doi:10.1099/0022-1317-50-9-822.
   PubMed Web of Science ®Google Scholar
• Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 2009;7:654–65. doi:10.1038/nrmicro2199.
   PubMed Web of Science ®Google Scholar
• Hood RD, Singh P, Hsu F, Guvener T, Carl MA, Trinidad RR, Silverman JM, Ohlson BB, Hicks KG, Plemel RL, et al. A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria. Cell Host Microbe. 2010;7:25–37. doi:10.1016/j.chom.2009.12.007.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu Y-C, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21. doi:10.1002/hep.20701.
   PubMed Web of Science ®Google Scholar